Sulbactam-durlobactam for anti-infection treatment after lung transplantation

Objective  To summarize the clinical experience of the first case of sulbactam-durlobactam treatment for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation in China.

Methods  A retrospective analysis was conducted on a case of a patient with severe chronic obstructive pulmonary disease who received sulbactam-durlobactam treatment after lung transplantation.

Results  A 68-year-old male patient with a history of drug-resistant Acinetobacter baumannii infection before surgery, experienced worsening infection and impaired renal function after lung transplantation, with sputum culture showing extensively drug-resistant Acinetobacter baumannii. After receiving combination treatment with sulbactam-durlobactam and meropenem, the infection was controlled, and the function of the transplanted lung was restored.

Conclusions  Sulbactam-durlobactam has potential therapeutic value for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation and provides a new strategy for clinical practice.